Mobilan is a clinical-stage nanoparticle-formulated, recombinant non-replicating adenovirus that directs expression of Toll-like Receptor 5 (TLR5) and its agonistic ligand, flagellin.
In preclinical studies, delivery of Mobilan to tumor cells caused constant TLR5 signaling that induced innate immune response to the tumor with subsequent development of adaptive immune response. Primary indications for Mobilan include tumors expressing the Coxsackievirus and adenovirus receptor (CAR), such as prostate cancer, based on a companion diagnostic test.
A Phase 1 multicenter, randomized, placebo-controlled, single-blinded study evaluating single injections of ascending doses of Mobilan administered directly into the prostate of patients with prostate cancer is currently ongoing under an IND in the Russian Federation. This study is supported by a contract with the Russian Ministry of Industry and Trade.
Panacela, our joint venture, holds worldwide development and commercialization rights to Mobilan.